Dexcom (DXCM) Change in Accured Expenses (2010 - 2026)

Dexcom (DXCM) has 17 years of Change in Accured Expenses data on file, last reported at $145.1 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 15.71% year-over-year to $145.1 million in Q1 2026; TTM through Mar 2026 was $75.1 million, a 269.91% increase from a year earlier, with the FY2025 full-year figure at $55.4 million, up 192.33% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $145.1 million, up from -$1.2 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for DXCM reached as high as $449.9 million in Q4 2023 and fell as low as -$291.7 million in Q4 2024.
• Historically, Change in Accured Expenses has averaged $36.2 million across 5 years, with a median of $41.3 million in 2025.
• Across the five-year window, Change in Accured Expenses jumped 3264.89% in 2023 and sank 252.28% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$162.8 million in 2022, then jumped by 376.35% to $449.9 million in 2023, then slumped by 164.84% to -$291.7 million in 2024, then soared by 99.59% to -$1.2 million in 2025, then jumped by 12191.67% to $145.1 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $145.1 million in Q1 2026, -$1.2 million in Q4 2025, and $41.3 million in Q3 2025.